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FELD better not thinking of metastases only
when liver lesions appear after bleomycin-based
treatment for non-seminoma testis from
metastases
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and Winette TA van der Graaf1
Abstract
Background: Bleomycin has become an integral part of chemotherapy in patients with germ-cell tumors. One of
the most feared side effects is bleomycin-induced pneumonitis. In patients with mild or moderate BIP, radiological
signs disappear almost completely within nine months after discontinuation of bleomycin treatment.
Case presentation: We present a patient with a history of non seminoma of the testis and bleomycin-induced
pneumonitis. During follow-up, regression of the hypothesis of eosinophilic migration to the liver after regression of
bleomycin-induced pneumonitis is highly suspicious based on transient eosinophilia and focal eosinophilic liver
disease.
Conclusion: As follow up may consist of CT scanning in germ-line tumor patients, transient eosinophilic liver
lesions reported during regressive bleomycin-induced pneumonitis should not be presumed automatically as
metastatic tumor relapse and require further sequential imaging and pathological examination.
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Background
Bleomycin is a glycopeptide antibiotic produced by the
bacterium Streptomyces verticillus. Bleomycin acts as an
oncolytic agent by inducing DNA strand breakage and
subsequent has become an integral part of chemother-
apy in patients with germ-cell tumors [1,2]. Bleomycin-
induced toxicity usually targets organs with low hydrolase
concentrations i.e. lungs and skin [3]. One of the most
feared side effects is bleomycin-induced pneumonitis
(BIP) [4]. BIP is a potential life-threatening interstitial pul-
monary fibrosis. Depending on the diagnosis criteria used,
up to 46% of patients treated with bleomycin develop BIP
[4]. Treatment of BIP consists of discontinuation of bleo-
mycin. In severe BIP cases, steroids are indicated, while a
case-report mentions imatinib mesylate as a salvage
therapy in steroid-resistant BIP [4,5]. In patients with mild
or moderate BIP, radiological signs disappear almost
completely within nine months after discontinuation of
bleomycin treatment [6]. In this case-report, transient eo-
sinophilia and focal eosinophilic liver lesions occurred
simultaneously with regression of BIP lesions, fuelling the
hypothesis of eosinophilic migration. It implicates se-
quential computer tomography (CT) scanning and robust
pathologic evidence for diagnosing relapse of testicular
cancer in such cases.
Case presentation
A 41-year-old man was diagnosed with stage IIA good
risk non seminoma of the left-sided testis and treated
with hemiorchidectomy and adjuvant three cycles of
bleomycin, etoposide and cisplatin. He received a total
dose of 270 mg bleomycin during treatment. After the
last course of chemotherapy, a chest and abdominal
CT-scan (CT 1) revealed complete remission of the
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metastatic lesions. However, we unexpectedly discovered
fibrosis in both lungs with signs of bronchiolitis
obliterans and focally organizing pneumonia, probably
induced by bleomycin (Figure 1a), while liver lesions
were absent (Figure 1b). He had no pulmonary com-
plaints. No broncho-alveolar lavage was performed. Our
patient was closely monitored according to national
guidelines [7]. A year after end of chemotherapy, with
pulmonary infiltrations resolving (Figure 2a) routine CT
scan (CT 4) showed four new hypo-dense lesions in the
liver with a maximal diameter of 20 mm (Figure 2b. At
that moment, the patient reported no complaints.
Tumor markers, human chorionic gonadotropin, alpha
fetoprotein levels and lactate dehydrogenase, were nor-
mal. Laboratory findings reported 7.3×109/l leucocytes
with 11% eosinophils (absolute eosinophil count 0.8 ×
109/l, normal value < 0.5) normal liver enzymes, biliru-
bin level and liver function tests (prothrombin time, al-
bumin and glucose). The patient had no history of travel
related diseases, dietary habits and other risk factors for
eosinophilia. Sarcoidosis was ruled out by a normal
serum angiotensin-converting enzyme. Hepatitis ser-
ology and bacteriological cultures were all negative.
Additional, magnetic resonance imaging (MRI) was per-
formed for further characterization (Figure 3a and 3b).
On the non-contrast T1-weighted axial MRI image
(Figure 3a) a lesion with a hypointense rim and iso-
intense centre was seen. On the contrast enhanced T1-
weighted fat-suppressed axial MR image (hepatocyte
phase, Figure 3b) a lesion with centrally low signal inten-
sity and rim enhancement suggestive for small abscess
was seen. A needle biopsy of one of the liver lesions
showed no signs of tumor, normal architecture of central
veins and portal fields and portal inflammation with in-
filtration of eosinophils and lymphocytes with focal ne-
crosis (Figure 4). Extensive discussions in our tumor
panel and with our hepatology experts led to the diagno-
sis of bleomycin induced focal hepatitis with eosinophilic
a
b
Figure 1 Radiologic findings at the end of chemotherapy.
(a) Fibrosis in both lungs with signs of bronchiolitis obliterans and
focally organizing pneumonia; (b) No signs of liver lesions.
a
b
Figure 2 Radiologic findings one year after end of
chemotherapy. (a) Pulmonary infiltrations resolving; (b) Four new
hypo-dense lesions in the liver.
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infiltration based on exclusion of other possible diagno-
ses, time-relationship with BIP regression and pathologic
findings. A wait-and-see policy was adopted with CT
scanning (CT 6) three months later (Figure 5).
This CT revealed further regression of pulmonary fi-
brosis, and regression of liver lesions in segment 2 (n=1)
and in segment 8 (n=3). At 10 months one lesion was
further decreased 3 lesions were stable. Interestingly,
subsequent blood measurements showed a normali-
zation of the percentage eosinophils in the three months
between the first occurrence of liver lesions on CT and
second CT with diminishment of these liver lesions and
eventually calcification. This leads to the hypothesis that
both findings are related to each other (Figure 6).
Discussion
We have seen the concomittant regression of BIP and
onset of focal eosinophilic liver disease (FELD) with eo-
sinophilia. By exclusion diagnosis and thorough patho-
logic examination, this relationship in time led to the
hypothesis of eosinophilic migration. Our understanding
of the pathogenesis of BIP is mainly based on data de-
rived from animal studies. Endothelial damage of the
lung vasculature by bleomycin-induced free radicals is
associated with an acquired loss of bleomycin hydrolase
activity and followed by an influx of inflammatory cells
[8]. There is a significant correlation between eosino-
philia and bleomycin-induced pulmonary fibrosis [9,10].
Apart from T-lymphocytes, eosinophils are key players
in the production of tumor growth factor-β, platelet-
derived growth factor receptor-α and tumor necrosis
factor-α, leading to proliferation and accumulation of fi-
broblasts. On their turn, fibroblasts produce chemotactic
cytokines recruiting eosinophils [11,12]. The trigger for
the self-limiting nature of BIP remains elusive due to
a
b
Figure 3 Characterization by MRI. (a) Lesion with hypointense rim
and isointense centre; (b) Lesion with centrally low signal intensity
and rim enhancement.
Figure 4 Pathologic findings of one of the liver lesions
revealing portal inflammation, infiltration of eosinophils and
lymphocytes with focal necrosis.
Figure 5 Abdominal CT-scan fifteen months after end of
chemotherapy with further regression of pulmonary fibrosis,
and regression of liver lesions.
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complex interaction between several T-lymphocyte re-
lated chemokines [13,14]. We hypothesize that pulmo-
nary eosinophils and fibroblasts migrate to other organs
such as the liver, leading to transient eosinophila and
focal eosinophilic accumulation. FELD is a well-known
disease entity that is associated with a variety of patho-
logical conditions including parasitic infestations, allergy,
internal malignancies, drug hypersensitivity, and hy-
pereosinophilic syndrome [15,16]. FELD can be diffe-
rentiated from hepatic metastases using CT or MRI
scanning. A significant smaller lesion size on unen-
hanced T1-weighted compared to hepatocyte phase im-
aging (delayed phased) and an ill-defined margin and
isointensity on T1 weighted images can distinguish FELD
from liver hepatic metastases [17-19]. These characteris-
tics were also observed in our patient. The biopsy-proven
eosinophilic infiltrations had irregular, fuzzy margins,
while arterial hyperintensity was lacking. In our patient,
liver biopsy revealed typical FELD characteristics. Ne-
vertheless, after extensive biochemical, serological and
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Figure 6 Excel-file graph of absolute eosinophil count over time. Absolute eosinophil count, with a normal value of < 0,5 × 109/l OK=
operation orchidectomy BEP= chemotherapy course with Bleomycine, Etoposide and Cisplatin CT1 = CT scan with bilateral pulmonary
infiltrations, no liver abnormalities (Figure 1) CT2 = CT scan with decreased pulmonary fibrosis, no liver abnormalities CT3 = CT scan with
decreased pulmonary fibrosis, no liver abnormalities CT4 = CT scan with remains of pulmonary fibrosis and 4 liver lesions (Figure 2) MRI = MRI
liver, 4 liver lesions (Figure 3a and 3b) CT5 = CT scan with remains of pulmonary fibrosis and 4 decreased liver lesions CT6 = CT scan with
remains of pulmonary fibrosis and 3 liver lesions stable, 1 decreased (Figure 5) CT7 = CT scan with remains of pulmonary fibrosis and 4 liver
lesions stable with central calcifications.
Table 1 Differential diagnosis between metastatic liver lesions and FELD
Metastatic liver lesion FELD
Incidence/100,000 8 – 20 3 – 4
Solitary 5 – 10% 90%
Pathogenesis Hematogenous or lymphatic spread of cancer parasitic infestations, allergy, internal malignancies,
drug hypersensitivity, and hypereosinophilic syndrome
Imaging US, CT Two-phase dynamic CT, MRI
Alpha fetoprotein; human chorionic
gonadotropin
Elevated (in case of non-seminoma testis) Normal
Calcification Possible None
Characteristic gross features Hemorrhage, necrosis with rim enhancement
on CT, spherical shape
indistinct margins, absence of rim enhancement,
nonspherical shape
Characteristic microscopic features Replacement of hepatocytes, by malignant cells
no portal structures
focal eosinophilic accumulation
Diagnosis FNAB or core biopsy FNAB or core biopsy
Treatment Resection, RFA or chemotherapy Depending underlying disease
US: ultrasound; CT: computerized tomography; MRI: magnetic resonance imaging; FNAB: fine needle aspiration biopsy for cytology; RFA: radiation
frequency ablation.
De Vos et al. BMC Cancer 2013, 13:491 Page 4 of 5
http://www.biomedcentral.com/1471-2407/13/491
bacteriological testing, no specific cause, related to a tran-
sient appearance of eosinophilia and eosinophil infiltration
in the liver, was determined. Yet, a clear time-relationship
was observed between eosinophilia and the onset of pul-
monary fibrosis and liver lesions and normalization of eo-
sinophil count and regression of pulmonary fibrosis and
liver lesions (Figure 6). This lead to the hypothesis of in-
terrelated cause and effect. Focal liver lesions in patients
with BIP do not necessarily imply the relapse of germcell
tumors as is demonstrated in our case. It is always a chal-
lenge to differentiate between metastatic or nonmetastatic
liver lesions (Table 1). It is likely that corticosteroids given
for BIP, for example in case of severe pulmonary symp-
toms, would ameliorate the intense inflammatory reaction
[4,20]. However, as corticosteroids have not direct effect
on the initial inflammatory reaction leading to BIP, our pa-
tient would not have benefited and the liver lesions would
probably still have emerged.
Conclusion
In this patient the hypothesis of eosinophilic migration
to the liver after regression of BIP is suggestive given the
transient eosinophilia and presence of FELD. As follow
up may consist of CT scanning in germ-line tumor pa-
tients, transient eosinophilic liver lesions reported dur-
ing regressive BIP should not be presumed automatically
as metastatic tumor relapse and require further sequen-
tial imaging and pathological examination.
Consent
Patient has given his consent for publication of case-
report.
Abbreviations
BIP: Bleomycin-induced pneumonitis; CT: Computer tomography; FELD: Focal
eosinophilic liver disease; MRI: Magnetic resonance imaging.
Competing interests
No funding sources need to be credited. No conflicts of interest should
bementioned.
Authors’ contributions
IN provided the figures of pathological findings. JF provided the figures of
radiological findings. All authors read and approved the final manuscript.
Acknowledgements
No grant support needs to be reported. Data from the manuscript were not
presented at previous meetings. No disclaimers have to be made.
Author details
1Department of Medical Oncology, Radboud University Nijmegen Medical
Centre, P.O. Box 9101, 6500 HB Nijmegen, Netherlands. 2Department of
Gastroenterology and Hepatology, Radboud University, Nijmegen Medical
Centre, P.O. Box 9101, 6500 HB Nijmegen, Netherlands. 3Department of
Pathology, Radboud University Nijmegen Medical Centre, P.O. Box 9101,
6500 HB Nijmegen, Netherlands. 4Department of Radiology, Radboud
University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen,
Netherlands.
Received: 30 November 2012 Accepted: 20 September 2013
Published: 22 October 2013
References
1. de Wit R, Stoter G, Sleijfer DT, Kaye SB, de Mulder PH, ten Bokkel Huinink
WW, Spaander PJ, de Pauw M, Sylvester R: Four cycles of BEP versus an
alternating regimen of PVB and BEP in patients with poorprognosis
metastatic testicular non-seminoma; a randomized study of the EORTC
Genitourinary Tract Cancer Cooperative Group. Br J - Cancer 1995,
71:1311–1314. 1195.
2. de Wit R, Stoter G, Sleijfer DT, Neijt JP, Ten Bokkel Huinink WW D, Prijck L,
Collette L, Sylvester R: Four cycles of BEP vs. four cycles of VIP in patients
with intermediate-prognosis metastatic testicular nonseminoma: a
randomized study of the EORTC Genitourinary Tract Cancer Cooperative
Group. Br J Cancer 1998, 78:828–832.
3. Sikic BI: Biochemical and cellular determinants of bleomycin cytotoxicity.
Cancer Surv 1986, 5:81–91.
4. Sleijfer S: Bleomycin-induced pneumonitis. Chest 2001, 120:617–624.
5. Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, Sangiolo D, Fizzotti M,
Caravelli D, Capaldi A, Anselmetti G, Palesandro E, D’Ambrosio L, Coha V,
Obert R, Aglietta M, Grignani G: Complete resolution of lifethreatening
bleomycin-induced pneumonitis after treatment with imatinib mesylate
in a patient with Hodgkin’s lymphoma: hope for severe chemotherapy-
induced toxicity? J Clin Oncol 2011, 29:691–693.
6. Bellamy EA, Husband JE, Blaquiere RM, Law MR: Bleomycin-related lung
damage: CT evidence. Radiology 1985, 156:155–158.
7. de Wit R, Gietema JA, de Reijke TM, Battermann JJ, van den Bergh ACM, van
Gils FCJM, de Kaa CA H-v, de Jong IJ, Los M, van Moorselaar RJA, Witjes JA:
Testicarcinoom: landelijke richtlijn. http://www.oncoline.nl/testiscarcinoom.
8. Filderman AE, Genovese LA, Lazo JS: Alterations in pulmonary protective
enzymes following systemic bleomycin treatment in mice. Biochem
Pharmacol 1988, 37:1111–1116.
9. Huaux F, Liu T, McGarry B, Ullenbruch M, Xing Z, Phan SH: Eosinophils and
T-lymphocytes possess distinct roles in bleomycininduced lung injury
and fibrosis. J Immunol 2003, 171:5470–5481.
10. Cui T, Kusunose M, Hamada A, Ono M, Miyamura M, Yoshioka S, Kyotani S,
Nishioka Y: Relationship between the eosinophilia of bronchoalveolar
lavage fluid (BALF) and the severity of pulmonary fibrosis induced by
bleomycin in rats. Biol Pharm Bull 2003, 26:959–963.
11. Sato E, Koyama S, Robbins RA: Bleomycin stimulates lung fibroblast and
epithelial cell lines to release eosinophil chemotactic activity. Eur Respir J
2000, 16:951–958.
12. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA,
Keane MP, Strieter RM: Circulating fibrocytes traffic to the lungs in
response to CXCL 12 and mediate fibrosis. J Clin Invest 2004, 114:438–446.
13. Mehrad B, Burdick MD, Strieter RM: Fibrocyte CXCR4 regulation as a
therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009,
41:1708–1718.
14. Pochetuhen K, Luzina IG, Lockatell V, Choi J, Todd NW, Atamas SP: Complex
regulation of pulmonary inflammation and fibrosis by CCL18. Am J
Pathol 2007, 171:428–437.
15. Kim GB, Kwon JH, Kang DS: Hypereosinophilic syndrome: imaging
findings in patients with hepatic involvement. Am J Roentgenol 1993,
161:577–580.
16. Lee WJ, Lim HK, Lim JH, Kim SH, Choi SH, Lee SJ: Foci of eosinophilrelated
necrosis in the liver: imaging findings and correlation with eosinophilia.
Am J Roentgenol 1999, 172:1255–1261.
17. Hur J, Park MS, Yu JS, Lim JS, Hong SW, Kim KW: Focal eosinophilic
necrosis versus metastasis in the liver: the usefulness of two-phase
dynamic CT. Am J Roentgenol 2005, 184:1085–1090.
18. Kim YK, Lee YH, Kim CS, Lee MW: Differentiating focal eosinophilic liver
disease from hepatic metastases using enhanced and gadoxetic acid-
enhanced MRI. Abdom Imaging 2011, 36:425–432.
19. Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, Lucena MI,
Castiella A, Lindor K, Björnsson E: The use of liver biopsy evaluation in
discrimination of idiopathic autoimmune hepatitis versus drug-induced
liver injury. Hepatology 2011, 54:931–939.
20. White DA, Stover DE: Severe bleomycin-induced pneumonitis Clinical
features and response to corticosteroids. Chest 1984, 86:723–728.
doi:10.1186/1471-2407-13-491
Cite this article as: De Vos et al.: FELD better not thinking of metastases
only when liver lesions appear after bleomycin-based treatment for
non-seminoma testis from metastases. BMC Cancer 2013 13:491.
De Vos et al. BMC Cancer 2013, 13:491 Page 5 of 5
http://www.biomedcentral.com/1471-2407/13/491
